Heidi Anne Duerr, MPH

Expert insights on the latest issues in wounds as well as HS resources are shared at the annual meeting.

Using pooled 52-week results from TRuE-AD1 and TRuE-AD2, investigators examined how the topical JAK1/JAK 2 inhibitor affects patient feelings of skin pain, discomfort, anxiety, and depression.

After reporting initial data earlier this year, investigators presented a fuller analysis in a poster at the 2022 SDPA Annual Fall Dermatology Conference.

The greatest improvements in quality of life measures were seen in the 300 mg tralokinumab group.